Key Metrics of Emergent Biosolutions
Revenue$1.0B▼ 6.1% YoYFY 2023
Operating income−$726M▼ 327.3% YoY
Net profit−$761M▼ 259.4% YoY
Shareholders' equity$649M
Market cap$370MEBS · $7.22
Competitors10identified
Open jobs2
About Emergent Biosolutions
Part of Emergent BioSolutions.
Sectors
Company details
- Website
- emergentbiosolutions.com
- Founded
- 2006
- Listed
- NYSE: EBS (since 2006)
Operational Areas of Emergent Biosolutions
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameEmergent BioSolutions Inc.
TickerEBS
ExchangeNYSE
CountryUnited States
SEC CIK0001367644
Listed since2006
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Websitehttp://emergentbiosolutions.com
US market & SEC filings
EBS · NYSE · SEC CIK 0001367644
Last price · 30 Oct 2026
$7.22
+1.83%
Market cap$370M
P/E—On FY 2023 diluted EPS
Volume682,401
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2006
EBS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeGaithersburg
GSTIN—
Email—
Websitehttp://emergentbiosolutions.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Emergent Biosolutions
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Group companies
Part of Emergent BioSolutions
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.